Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score.
Rebecca A Russell1, Nancy S Ghanayem, Evelyn M Kuhn
1Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
World Journal for Pediatric & Congenital Heart Surgery
|January 10, 2014
Summary
Risk-adjustment tools like RACHS-1 and ABC scores show a weak correlation with postoperative organ dysfunction (PELOD) in congenital heart disease (CHD) patients. A better morbidity metric is needed for CHD risk assessment.
Area of Science:
- Pediatric Cardiology
- Surgical Risk Assessment
- Healthcare Quality Improvement
Background:
- Congenital heart disease (CHD) patient outcomes are typically measured by mortality.
- Low mortality rates in CHD make mortality an insufficient primary outcome measure.
- Risk-adjustment tools (RACHS-1, ABC) correlate with mortality, but an alternative outcome is needed.
Purpose of the Study:
- To assess the correlation between established risk-adjustment tools and postoperative organ dysfunction in pediatric CHD patients.
- To determine if the Pediatric Logistic Organ Dysfunction (PELOD) score can serve as a reliable alternative outcome measure for risk-adjusted comparisons.
Main Methods:
- Utilized data from the Virtual PICU Systems database (2009-2010) for postoperative CHD patients.
- Employed Spearman rank correlation to examine relationships between RACHS-1/ABC scores and PELOD scores.
- Used Kruskal-Wallis analysis to assess PELOD score consistency across institutions.
Main Results:
- Analyzed 1,981 patient cases from 12 institutions.
- Found statistically significant, positive correlations between RACHS-1 and PELOD (r s = .353) and between ABC and PELOD (r s = .328).
- Observed significant variability in PELOD scores across centers for similar case complexities (P < .04).
Conclusions:
- RACHS-1 categories and ABC levels correlate with postoperative organ dysfunction (PELOD) in CHD.
- The observed correlation was weak, suggesting potential limitations of the PELOD score.
- Further research is required to identify a more accurate morbidity metric for CHD patients.
More Related Videos
Related Concept Videos
Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Odds Ratio
2.3K
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
2.3K


